Direct Healthcare Professional Communication (DHPC) on Paxlovid (nirmatrelvir, ritonavir): drug interactions with certain immunosuppressants, including tacrolimus
2024.03.21
Active substance: nirmatrelvir, ritonavir
Pfizer, in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM), informs that the concomitant administration of paxlovid and certain immunosuppressants with a narrow therapeutic range, such as calcineurin inhibitors (ciclosporin, tacrolimus) and mTOR inhibitors (everolimus, sirolimus), can lead to life-threatening and fatal reactions due to pharmacokinetic interactions.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN